- Home
- INMD vs PHAR Comparison
INMD vs PHAR Comparison
Compare INMD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMD
- PHAR
- Stock Information
- Founded
- INMD 2008
- PHAR 1988
- Country
- INMD Israel
- PHAR Netherlands
- Employees
- INMD N/A
- PHAR N/A
- Industry
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- INMD Health Care
- PHAR Health Care
- Exchange
- INMD Nasdaq
- PHAR Nasdaq
- Market Cap
- INMD 887.0M
- PHAR 718.1M
- IPO Year
- INMD 2019
- PHAR N/A
- Fundamental
- Price
- INMD $13.28
- PHAR $10.45
- Analyst Decision
- INMD Hold
- PHAR Strong Buy
- Analyst Count
- INMD 6
- PHAR 3
- Target Price
- INMD $17.56
- PHAR $30.00
- AVG Volume (30 Days)
- INMD 1.1M
- PHAR 2.6K
- Earning Date
- INMD 07-31-2025
- PHAR 07-31-2025
- Dividend Yield
- INMD N/A
- PHAR N/A
- EPS Growth
- INMD 8.69
- PHAR N/A
- EPS
- INMD 2.29
- PHAR N/A
- Revenue
- INMD $392,408,000.00
- PHAR $320,708,000.00
- Revenue This Year
- INMD $0.16
- PHAR $13.31
- Revenue Next Year
- INMD $4.84
- PHAR $7.68
- P/E Ratio
- INMD $5.79
- PHAR N/A
- Revenue Growth
- INMD N/A
- PHAR 24.13
- 52 Week Low
- INMD $13.16
- PHAR $6.65
- 52 Week High
- INMD $19.85
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- INMD 33.86
- PHAR 47.51
- Support Level
- INMD $13.16
- PHAR $10.41
- Resistance Level
- INMD $13.67
- PHAR $11.50
- Average True Range (ATR)
- INMD 0.40
- PHAR 0.32
- MACD
- INMD -0.09
- PHAR -0.17
- Stochastic Oscillator
- INMD 7.23
- PHAR 2.26
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.